Clinical Trial Results:
A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in combination with a background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibitors in antiretroviral-naïve HIV-1 infected subjects
Summary
|
|
EudraCT number |
2007-002647-25 |
Trial protocol |
BE DE FR PT GB IT |
Global completion date |
08 Feb 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
15 Oct 2016
|
First version publication date |
15 Oct 2016
|
Other versions |
|
Summary report(s) |
TMC278-TIDP6-C215 (2007-002647-25)_Ct.gov result |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.